- Report
- October 2024
- 188 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 293 Pages
Global
From €3185EUR$3,500USD£2,731GBP
€4551EUR$5,000USD£3,901GBP
- Report
- July 2024
- 135 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- May 2023
- 98 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- August 2023
- 85 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- December 2019
United States
From €3636EUR$3,995USD£3,117GBP
- Book
- July 2023
- 1568 Pages
Mepivacaine is a local anesthetic drug used to numb a specific area of the body. It is a member of the amide class of anesthetics, which are commonly used in dentistry and minor surgical procedures. Mepivacaine is administered through injection, and is known for its fast onset and short duration of action. It is also used to reduce pain during labor and delivery.
Mepivacaine is one of the most widely used anesthetic drugs in the world. It is available in a variety of formulations, including aqueous solutions, liposomal suspensions, and topical gels. It is also available in combination with other drugs, such as epinephrine, to prolong its effects.
The market for mepivacaine is highly competitive, with many companies offering their own formulations of the drug. Some of the major players in the market include Pfizer, Novartis, Sanofi, Mylan, and Teva Pharmaceuticals. Show Less Read more